17293601

Source:http://linkedlifedata.com/resource/pubmed/id/17293601

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0014939, umls-concept:C0144576, umls-concept:C0332161, umls-concept:C0332174, umls-concept:C0677874, umls-concept:C0796419, umls-concept:C1512693, umls-concept:C1521733, umls-concept:C1521828, umls-concept:C2347669
pubmed:issue	5
pubmed:dateCreated	2007-5-9
pubmed:abstractText	We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC).
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/R01-CA106290
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Bridged Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/taxane
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0923-7534
pubmed:author	pubmed-author:AndersonKK, pubmed-author:AndreFF, pubmed-author:BuchholzT ATA, pubmed-author:BuzdarA UAU, pubmed-author:DykeP CPC, pubmed-author:Gonzalez-AnguloA MAM, pubmed-author:HessK RKR, pubmed-author:HortobagyiG NGN, pubmed-author:KauS-WSW, pubmed-author:KuererH MHM, pubmed-author:MazouniCC, pubmed-author:PusztaiLL, pubmed-author:SymmansW FWF
pubmed:issnType	Print
pubmed:volume	18
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	874-80
pubmed:dateRevised	2007-12-3
pubmed:meshHeading	pubmed-meshheading:17293601-Adult, pubmed-meshheading:17293601-Aged, pubmed-meshheading:17293601-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:17293601-Breast Neoplasms, pubmed-meshheading:17293601-Bridged Compounds, pubmed-meshheading:17293601-Chemotherapy, Adjuvant, pubmed-meshheading:17293601-Cyclophosphamide, pubmed-meshheading:17293601-Doxorubicin, pubmed-meshheading:17293601-Drug Administration Schedule, pubmed-meshheading:17293601-Female, pubmed-meshheading:17293601-Fluorouracil, pubmed-meshheading:17293601-Humans, pubmed-meshheading:17293601-Middle Aged, pubmed-meshheading:17293601-Neoplasms, Hormone-Dependent, pubmed-meshheading:17293601-Paclitaxel, pubmed-meshheading:17293601-Prognosis, pubmed-meshheading:17293601-Receptors, Estrogen, pubmed-meshheading:17293601-Survival Analysis, pubmed-meshheading:17293601-Taxoids, pubmed-meshheading:17293601-Tumor Burden
pubmed:year	2007
pubmed:articleTitle	Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
pubmed:affiliation	Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Meta-Analysis, Research Support, N.I.H., Extramural